BJU Int

1. TAKAHASHI T
   The first step in shared decision-making for prostate cancer screening.
   BJU Int. 2024 Nov 6. doi: 10.1111/bju.16580.
   

   >> Share

   
   
2. RANS K, Goffin K, Joniau S, Daugaard G, et al
   The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial.
   BJU Int. 2024 Nov 6. doi: 10.1111/bju.16574.
   

   >> Share

   
   

   
   BMC Cancer

3. SHAO IH, Chen SY, Chen HY, Sheng TW, et al
   Integrating clinical and image-based parameters for prediction of early post-prostatectomy incontinence recovery: simplified nomogram approach.
   BMC Cancer. 2024;24:1344.
   

   >> Share

   
   

   
   BMC Urol

4. LUO X, Wen W
   MicroRNA in prostate cancer: from biogenesis to applicative potential.
   BMC Urol. 2024;24:244.
   

   >> Share

   
   

   
   Cancer

5. SRIVASTAVA A, Liu X, Maganty A, Kaufman SR, et al
   Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare.
   Cancer. 2024 Nov 5. doi: 10.1002/cncr.35633.
   

   >> Share

   
   
6. SOERENSEN SJC, Lim DS, Montez-Rath ME, Chertow GM, et al
   Pesticides and prostate cancer incidence and mortality: An environment-wide association study.
   Cancer. 2024 Nov 4. doi: 10.1002/cncr.35572.
   

   >> Share

   
   

   
   Cancer Lett

7. GURUVAYURAPPAN GK, Frankenbach-Desor T, Laubach M, Klein A, et al
   Clinical Challenges in Prostate Cancer Management: Metastatic Bone-tropism and The Role of Circulating Tumor Cells.
   Cancer Lett. 2024 Oct 30:217310. doi: 10.1016/j.canlet.2024.217310.
   

   >> Share

   
   

   
   Cancer Res

8. MCQUILLEN CN, Brady NJ
   ASCL1 Drives the Development of Neuroendocrine Prostate Cancer.
   Cancer Res. 2024;84:3499-3501.
   

   >> Share

   
   

   
   Clin Cancer Res

9. NAWFAL R, El Hajj Chehade R, Berchuck JE
   Unearthing a prostate cancer cfDNA signature that "stems" from AR alterations.
   Clin Cancer Res. 2024 Nov 4. doi: 10.1158/1078-0432.CCR-24-2849.
   

   >> Share

   
   

   
   Endocrinology

10. 
    Correction to: "Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells".
    Endocrinology. 2024;165:bqae145.
    

    >> Share

    
    

    
    Eur Radiol

11. RATA M, Orton MR, Tunariu N, Curcean A, et al
    Repeatability of quantitative MR fingerprinting for T(1) and T(2) measurements of metastatic bone in prostate cancer patients.
    Eur Radiol. 2024 Nov 6. doi: 10.1007/s00330-024-11162.
    

    >> Share

    
    

    
    Eur Urol

12. SHAW G, Kelly JD, Roobol MJ
    Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.
    Eur Urol. 2023 Oct 26:S0302-2838(23)03170-6. doi: 10.1016/j.eururo.2023.
    

    >> Share

    
    

    
    Int J Urol

13. HAKOZAKI Y, Yamada Y, Fujimura T, Kimura N, et al
    Novel clipping procedure for preventing post-operative inguinal hernia in robot-assisted radical prostatectomy.
    Int J Urol. 2024;31:1241-1247.
    

    >> Share

    
    

    
    J Nucl Med

14. CALAIS J, Morris MJ, Kendi AT, Kalebasty AR, et al
    Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Oct 3:jnumed.124.268363. doi: 10.2967/jnumed.124.268363.
    

    >> Share

    
    
15. SAIDI A, Stallons TA, Wong AG, Torgue JJ, et al
    Preclinical Investigation of [(212)Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model.
    J Nucl Med. 2024;65:1769-1775.
    

    >> Share

    
    
16. BERNARDINO RM, Lajkosz K, Yin LB, Sayyid RK, et al
    Association of Free-to-Total PSA Ratio and (18)F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.267877. doi: 10.2967/jnumed.124.267877.
    

    >> Share

    
    
17. POULIOT F, Saad F, Rousseau E, Richard PO, et al
    Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.268020. doi: 10.2967/jnumed.124.268020.
    

    >> Share

    
    

    
    Nat Rev Urol

18. NIK-AHD F, Anger JT, Cooperberg MR, Freedland SJ, et al
    Prostate cancer in transgender women - challenges in research and clinical care.
    Nat Rev Urol. 2024 Nov 4. doi: 10.1038/s41585-024-00966.
    

    >> Share

    
    

    
    Oncogene

19. HUANG H, Zhuang X, Yin S, Sun W, et al
    The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive progression of prostate cancer.
    Oncogene. 2024 Nov 2. doi: 10.1038/s41388-024-03209.
    

    >> Share

    
    

    
    Prostate

20. TAO H, Wu F, Li R, Du X, et al
    Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer.
    Prostate. 2024 Nov 3. doi: 10.1002/pros.24817.
    

    >> Share

    
    
21. ZHAO X, Sakamoto S, Ishikawa H, Yamada Y, et al
    Significant Effect of Carbon-Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High-Risk Prostate Cancer Patients: A Two-Center Controlled Trial Compare With X-Ray External Beam Radiation Therapy.
    Prostate. 2024 Nov 3. doi: 10.1002/pros.24818.
    

    >> Share

    
    

    
    Urology

22. SHORE N, Brown G, Lowentritt B, O'Donnell L, et al
    Evaluating the Importance of Practice-Level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology.
    Urology. 2024 Nov 1:S0090-4295(24)00950-6. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share